Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Toxicology and Applied Pharmacology

• Publication date

  2014-05-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.taap.2014.03.002PMID 24632081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liposomal drug delivery systems: from concept to clinical applications.

  2013cited by this paper
• State of the art in PEGylation: the great versatility achieved after forty years of research.

  2012cited by this paper
• Accelerated Blood Clearance of PEGylated PLGA Nanoparticles Following Repeated Injections: Effects of Polymer Dose, PEG Coating, and Encapsulated Anticancer Drug

  2012cited by this paper
• Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates

  2012cited by this paper
• Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.

  2011cited by this paper
• A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.

  2011cited by this paper
• Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.

  2011cited by this paper
• Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies.

  2010cited by this paper
• Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.

  2009cited by this paper
• Antigen‐specific B cell detection reagents: Use and quality control

  2008cited by this paper
• PEG-uricase in the management of treatment-resistant gout and hyperuricemia.

  2008cited by this paper
• Maintenance therapy with certolizumab pegol for Crohn's disease.

  2007cited by this paper
• Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.

  2007influential reference
• Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients

  2007cited by this paper
• Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.

  2006influential reference
• Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles.

  2005cited by this paper
• PEGylation, successful approach to drug delivery.

  2005cited by this paper
• Peginterferon alfa-2a: a review of approved and investigational uses.

  2004cited by this paper
• Pegaspargase: a review of clinical studies.

  2003cited by this paper
• In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.

  2003cited by this paper
• A Dose-Escalating Pilot Study of Sterically Stabilized, Pegylated Liposomal Doxorubicin (Lipo-Dox®) in Patients with Metastatic Breast Cancer

  2003cited by this paper
• Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.

  2003cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins.

  2002cited by this paper
• Chemistry for peptide and protein PEGylation.

  2002cited by this paper
• Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.

  1999cited by this paper
• Terminal modifications inhibit proteolytic degradation of an immunogenic mart‐127–35 peptide: Implications for peptide vaccines

  1999cited by this paper
• Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

  1995cited by this paper
• Kinetic analysis of AUC-dependent saturable clearance of liposomes: Mathematical description of AUC dependency

  1993cited by this paper
• Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.

  1991cited by this paper
• Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.

  1983cited by this paper
• The proteolytic activation systems of complement.

  1981cited by this paper
• Colorimetric assay methods for free and phosphorylated glyceric acids.

  1959cited by this paper

• Pharmacological characterization and neuroprotective efficacy of ZHB103, a novel long-acting rhKLK1.

  2026cites this paper
• AFM-Based Single-Molecule Force Spectroscopy of PEG–Anti-PEG Antibody Interactions

  2026cites this paper
• Unravelling the Potential of Zwitterionic Polymers in Molecular Imprinting.

  2025cites this paper
• The strategy used by naïve anti-PEG antibodies to capture flexible and featureless PEG chains.

  2025cites this paper
• Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.

  2024cites this paper
• Direct Quantification of Serum Protein Interactions with PEGylated Micelle Nanocarriers.

  2023cites this paper
• Distinguishing anti-PEG antibodies by specificity for the PEG terminus using nanoarchitectonics-based antibiofouling cello-oligosaccharide platforms.

  2023cites this paper
• Conjugation and encapsulation of L-asparaginase: an effective strategy for augmenting enzyme potential for anticancer activity

  2023cites this paper
• Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.

  2023cites this paper
• Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities

  2023cites this paper
• Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor

  2023cites this paper
• Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice.

  2023cites this paper
• Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation.

  2022cites this paper
• Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy

  2022cites this paper
• A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.

  2022cites this paper
• Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity.

  2021cites this paper
• Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals

  2021cites this paper
• Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals

  2021cites this paper
• Enhancement of bioactivity, thermal stability and tumor retention by self-fused concatenation of green fluorescent protein

  2021cites this paper
• Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon alfa-2a (Pegasys®) in mice.

  2020cites this paper
• Liposomes and PEGylated liposomes as drug delivery system

  2020cites this paper
• An immediate hypersensitivity reaction induced by PEGylated recombinant factor VIII

  2020cites this paper
• The Contribution of PEG Molecular Weights in PEGylated Emulsions to the Various Phases in the Accelerated Blood Clearance (ABC) Phenomenon in Rats

  2020cites this paper
• Shielding of Hepatitis B Virus-Like Nanoparticle with Poly(2-Ethyl-2-Oxazoline)

  2019cites this paper
• Site-specific PEGylation crosslinking of L-asparaginase subunits to improve its therapeutic efficiency

  2018cites this paper
• Thiol-maleimide poly(ethylene glycol) crosslinking of L-asparaginase subunits at recombinant cysteine residues introduced by mutagenesis

  2018cites this paper
• A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics

  2018cites this paper
• Comparison among different “revealers” in the study of accelerated blood clearance phenomenon

  2018cites this paper
• Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

  2016influential citation
• Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View

  2016cites this paper
• Poly（ethylene glycol）に対する抗体の特性、評価、抑制

  2016cites this paper
• Polymer-drug nanoconjugate – an innovative nanomedicine: challenges and recent advancements in rational formulation design for effective delivery of poorly soluble drugs.

  2016cites this paper
• Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.

  2016cites this paper
• Pharmaceutical Polymers: Bioactive and Synthetic Hybrid Polymers

  2015cites this paper
• Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.

  2015cites this paper
• Effect of Repeated Injections of Adenosine Diphosphate-Encapsulated Liposomes Coated with a Fibrinogen γ-Chain Dodecapeptide Developed as a Synthetic Platelet Substitute on Accelerated Blood Clearance in a Healthy and an Anticancer Drug-Induced Thrombocytopenia Rat Model.

  2015cites this paper
• Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.

  2015cites this paper
• Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.

  2015cites this paper
• Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs

  2015cites this paper
• Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.

  2015cites this paper
• Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01

  2015cites this paper
• Polymer therapeutics: Top 10 selling pharmaceuticals - what next?

  2014cites this paper